Clinical Evaluation of Parthadyarishta (Arjunarishta) and Sarpagandha Vati in the management of Essential Hypertension (Uccha Raktachap)

Central Council For Research In Ayurvedic Sciences0 个研究点目标入组 76 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Diagnosed patients of essential hypertension S.B.P. >= 140 Hg. and_ < 159 Hg.D.B.P. _ > 90 Hg. and _ < 99 Hg mm Hg (Hypertension Stage-1,as per J N C VII report,2004)
•2. Willing and able to participate for 14 weeks

•1. Known clinical diagnosed cases of coronary diseases
•2. Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
•3. Symptomatic patients with clinical evidence of Heart failure.
•4. Secondary hypertension.
•5 Patients with concurrent serious Hepatic Dysfunction (defined as AST and/or ALT >3 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine >1.2mg/dl, uncontrolled Pulmonary Dysfunction(asthmatic and COPD patients) or other concurrent severe disease.
•6.Patients with Diabetes Mellitus {B.S. (F) > 126 mg/dl and / or B.S. (2 hr. PP) >200 mg/dl}
•7. Women who are pregnant or lactating.
•8. Patients on steroids, oral contraceptive pills or estrogen replacement therapy.
•9. Alcoholics and/or drug abusers.
•10.Serum Triglycerides >= 250 mg/dl
•11.Patients with evidence of malignancy
•12. Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro-Endocrinal disorders, etc.)
•13. H/o hypersensitivity to any of the trial drugs or their ingredients.
•14. Patients who have completed participation in any other clinical trial during the past six (06) months.
•15. Any other condition which the Investigator thinks may jeopardize the study.

发起方